Governments have consistently approached change as a coordinated exercise, bundling multiple elements into single negotiations rather than adjusting one lever at a time. This pattern has shaped outcomes across pricing, pharmacy agreements, and the evolution of both off-patent and innovative medicine sectors, and it continues to define how the next phase of reform is likely to unfold.
Those who recognise and respond to the reality will be better positioned to shape reforms
March 31, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 24 April
April 24, 2026 - - Podcast -
Prevention warning as Pfizer urges Budget reset on vaccines and immunisation
April 24, 2026 - -
NDIS fraud is so extensive that 'prosecuting our way out of it' is now impractical
April 24, 2026 - - Latest News -
Boehringer Ingelheim and Heart of Australia take mobile lung care deeper into regional Australia
April 24, 2026 - - Latest News -
A decade to diagnosis highlights hidden burden of immune disorders
April 24, 2026 - - Latest News -
Quiet diplomacy as Australia navigates global pricing pressure, but can it work?
April 24, 2026 - - Latest News -
New immunotherapy option approved for Australians with relapsed follicular lymphoma
April 24, 2026 - - Latest News
